Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NanoViricides, Inc. (NNVC) is advancing its antiviral drug candidate NV-387, originally developed for COVID-19, to explore broader applications against various viral infections. Pre-clinical studies show NV-387 exhibits activity against seasonal coronaviruses and SARS-CoV-2, aiming to serve as a broad-spectrum antiviral agent. The drug targets virus particles similarly to antibiotics targeting bacteria, with potential effectiveness against viruses like RSV and others. After successful Phase 1 trials, NV-387 could enter Phase 2 trials for multiple viral diseases, potentially optimizing development costs. Currently, the company is also focusing on therapeutics for the poxvirus family and other respiratory viruses, addressing the unmet need for safe and effective antiviral treatments.
NanoViricides, Inc. (NYSE American: NNVC) announced the shipment of drug products for the clinical trials of NV-CoV-2, its COVID-19 drug candidate, to collaborator Karveer Meditech Pvt. Ltd. in India. Karveer has secured regulatory approvals to conduct these trials, which are expected to start soon. NV-CoV-2 is designed to target SARS-CoV-2 and its evolving variants and has shown broad-spectrum efficacy and strong safety in preclinical studies. The drug will be available in oral syrup and gummies, as well as injectable and infusion forms for various patient populations. Unlike current antiviral treatments, NV-CoV-2 aims to treat all segments of the population, addressing unmet medical needs in the ongoing COVID-19 pandemic.
NanoViricides has signed a License Agreement with Karveer Meditech Pvt. Ltd. for the commercialization of its COVID drugs NV-CoV-2 and NV-CoV-2-R in India. Karveer will oversee the clinical development and has reportedly obtained necessary regulatory permissions. The human clinical trials are anticipated to commence shortly. Under the agreement, Karveer will conduct evaluations in compliance with local regulations, while NanoViricides retains rights to the data generated. Upon commercialization, NanoViricides will earn a 70% royalty on sales. This marks a significant milestone for the company in advancing its antiviral therapies.
NanoViricides, Inc. (NYSE American: NNVC) filed its Quarterly Report on Form 10-Q for Q1 FY2023 ending December 31, 2022, on February 14, 2023. The company reported cash and equivalents of approximately $11.5 million and $8.4 million in Property and Equipment. Liabilities stood at $0.46 million. The company anticipates higher cash expenditures as clinical trials for its lead drug candidate NV-CoV-2 for COVID-19 begin. NanoViricides has initiated the manufacture of clinical supply for NV-387 and expects to launch oral formulations for COVID-19 treatment, preparing for trials to address unmet needs in antiviral therapies.
NanoViricides (NYSE Amer.:NNVC) will present at the Biotech Showcase™ 2023 Conference in San Francisco on January 9 at 10:30 am PT. Dr. Anil Diwan will discuss the Company’s lead drug candidate, NV-CoV-2, for COVID-19 treatment and its broad-spectrum antiviral platform. This presentation aims to foster partnerships for drug development. The conference, running from January 9-11 at the Hilton San Francisco, is a networking opportunity for life sciences investors and executives.
NanoViricides, Inc. (NYSE Amer. NNVC) announced that its President, Dr. Anil Diwan, will present at the RHK Capital Disruptive Growth Conference in New York City on December 6, 2022, at 1:20 PM ET. The presentation will be accessible via webcast at this link. Dr. Diwan will discuss the lead drug candidate, NV-CoV-2, aimed at treating COVID-19 and long COVID, emphasizing its potential effectiveness against emerging variants.
Furthermore, he will outline the company's pipeline for other viral diseases.
NanoViricides, Inc. (NNVC) filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022, reporting cash and cash equivalents of approximately $13.1 million and total current liabilities of $0.51 million. The company aims to commence clinical trials for its lead drug candidate NV-CoV-2, designed to treat COVID-19. The IND application is nearing completion, pending engagement with a Clinical Research Organization (CRO). NV-CoV-2 is expected to effectively address COVID-19 and variants due to its broad-spectrum capabilities.
NanoViricides, Inc. (NYSE American: NNVC) filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022, detailing a current cash balance of approximately $14.4 Million and total current liabilities of $0.41 Million. The company is preparing an IND application for its lead drug candidate, NV-CoV-2, targeting SARS-CoV-2, with plans to conduct human clinical trials. Significant advances include developing an oral solution and a combination therapy with remdesivir. The company also reported a net loss of $8.1 Million for the fiscal year.
NanoViricides, Inc. (NYSE American: NNVC) announced the initiation of drug development targeting the monkeypox virus. The company plans to screen its broad-spectrum antiviral nanoviricides against poxviruses, aiming to create effective therapeutics. Currently, they are nearing completion of compound synthesis and have established a testing model in their lab. Their ongoing clinical trials for the SARS-CoV-2 drug candidate, NV-CoV-2, are expected to expedite this initiative. There is a pressing need for new treatments, especially as monkeypox cases surge globally.
NanoViricides has filed its quarterly report for Q3 of FY 2022, reporting $16 million in current assets and no revenues. With cash liabilities at approximately $0.4 million, the company's stockholder equity stands at $24.75 million. The firm plans to initiate human clinical trials for its COVID-19 drug candidate, NV-CoV-2, which has shown superior efficacy to remdesivir in animal studies. Additionally, it is developing formulations for oral and inhalation delivery. The company is also working on an antiviral for hAd41-F, related to severe hepatitis cases in children.